Last checked at 
NetScientific PLC - London-based life sciences and sustainability, technology investment and commercialisation firm - Says its subsidiary ProAxsis Ltd has received approval of a key US patent for the underlying technology associated with its brand-new K-POSTN Assay, which it expects to launch shortly. Says this is a "significant step" towards measuring bone health with a new innovation for patients at high risk of osteoporotic fractures.
Chief Executive Officer David Ribeiro says: "The K-POSTN assay has the potential to help Healthcare Professionals screen, identify and/or monitor people most at risk of osteoporotic fractures and other bone diseases, thus enabling early therapeutic intervention which will decrease the burden on the health service and increase quality of life for the patient.
"Furthermore, for Researchers and Pharmaceutical Companies seeking to develop new treatments for osteoporosis, the K-POSTN assay will deliver specific and quantifiable outcome measurements due to the rapid response shown by biomarkers to both anabolic and anticatabolic drugs."
Current stock price: 108.00 pence
Year-to-date change: more than doubled
By Arvind Bhunjun; arvindbhunjun@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
